Jörg Ruof

European Respiratory Society — Switzerland

Economics, Econometrics and Finance · Social Sciences

25h-index1.8kcitations95works2.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(58), Pharmaceutical Economics and Policy(27), Rheumatoid Arthritis Research and Therapies(21), Pharmaceutical studies and practices(19), Economic and Financial Impacts of Cancer(9)

Publications95 total

HPR4 Evolving HTA and Potential EU HTAR Ripple Effects in the US: Insights From a Stakeholder Survey
Value in Health·2025
Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy
Journal of Market Access & Health Policy·2025· 2 citedOpen Access
HPR68 How to Overcome the Remaining Challenges for Successful Implementation of the EU HTA Regulation: Key Insights From the 2023 European Access Academy Spring Convention and Survey
Value in Health·2024· 1 cited
PD226 Integration Of Patient And Clinician Insights Into The European Union Joint Scientific Consultations And Joint Clinical Assessments
International Journal of Technology Assessment in Health Care·2024Open Access
OP54 Different Perceptions Of Additional Benefit By Payers And Providers: Discrepant Voting Within G-BA’s Benefit Appraisals
International Journal of Technology Assessment in Health Care·2024Open Access
HPR133 The Global Impact of EU HTA: Insights From 13 Non-EU Countries
Value in Health·2024Open Access
Technology Assessment vs. Technology Appraisal—How to Strengthen the Science/Value Dichotomy with EU HTA?
Journal of Market Access & Health Policy·2024· 2 citedOpen Access
Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey
Health Policy and Technology·2024· 6 citedOpen Access
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy
Health Research Policy and Systems·2024· 8 citedOpen Access
The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy
Journal of Market Access & Health Policy·2024· 5 citedOpen Access
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
Journal of Market Access & Health Policy·2024· 7 citedOpen Access
Arzneimittel – Sicherheit, Nutzen und Zusatznutzen
Der Merkurstab·2024
Umgang mit best-verfügbarer Evidenz in der Nutzenbewertung von Arzneimitteln: Eine Analyse von Verfahren ohne Vorliegen einer randomisiert-kontrollierten Studie
Gesundheitsökonomie & Qualitätsmanagement·2023· 1 cited
The role of stakeholder involvement in the evolving EU HTA process: <i>Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire</i>
Journal of Market Access & Health Policy·2023· 13 citedOpen Access
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy
Health Economics Review·2022· 10 citedOpen Access
How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?
Health Economics Review·2022· 27 citedOpen Access
Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology–Based Tool to Support and Review Registries
Value in Health·2022· 23 cited
Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA’s Health Technology Assessments
Value in Health·2021· 2 cited
Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness &amp; safety?
Health Policy·2020· 11 cited
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
Health Economics Review·2019· 12 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Sonja Merkesdal(12), H. Zeidler(11), Thomas Mittendorf(10), Charalabos‐Markos Dintsios(8), Gerold Stucki(7), Jan L. Huelsemann(5), Thomas Staab(5), Wilfried Mau(4), Friedrich Wilhelm Schwartz(4), Andreas Maetzel(4), Fabrizio Gianfrate(4), Oriol Solà-Morales(4), Peter G. M. Mol(4), Ansgar Hebborn(4), J.-Matthias Graf von der Schulenburg(3), Alarcos Cieza(3), Pierre Ducournau(3), Elaine Julian(3), Johann‐Matthias Graf von der Schulenburg(3), J. L. Hülsemann(3)